Results 91 to 100 of about 41,518 (220)

A Real-Life Study in Patients Newly Diagnosed with Autoimmune Hashimoto’s Thyroiditis: Analysis of Asthenia as Admission Complaint

Life
Background: Amid the large panel of autoimmune thyroid diseases, Hashimoto’s thyroiditis (HT) represents a major point across multidisciplinary daily practice.
Ana Valea, Mihai Costachescu, Mihaela Stanciu, Claudiu Nistor, Oana-Claudia Sima, Mara Carsote, Tiberiu Vasile Ioan Nistor, Denisa Tanasescu, Florina Ligia Popa, Mihai-Lucian Ciobica   +9 more
doaj   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, EarlyView.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

International Journal of Cancer, Volume 158, Issue 9, Page 2429-2439, 1 May 2026.
What's new? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu, Li Zhang, Yun Fan, JianYing Zhou, Li Zhang, Qing Zhou, Wei Li, ChengPing Hu, GongYan Chen, Xin Zhang, CaiCun Zhou, Carmen González Arenas, Zhenghong Chen, Wen Cheng Yu, Tony S. K. Mok   +14 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Evaluation and Management of Thyroid Nodules: A Joint Consensus Statement From the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and Collaborating Bodies

Clinical Endocrinology, EarlyView.
Ram Moorthy, Saba P. Balasubramanian, Kate Farnell, Mairead Kelly, Gitta Madani, Mufaddal Moonim, Carla Moran, Julia Priestley, Michael Stechman, Emma Watts, Kristien Boelaert   +10 more
wiley   +1 more source

Multisystem Sarcoidosis Presenting With Hypercalcemia, Lytic Bone Lesion, and Mesenteric Panniculitis in Chronic Kidney Disease

Clinical Case Reports, Volume 14, Issue 4, April 2026.
The clinical photograph shows bilateral leg swelling with right‐sided predominance and cutaneous changes. CT images (A–C) demonstrate abdominal and retroperitoneal lymphadenopathy, and image D shows a hypodense lytic spinal lesion, suggesting multifocal disease involving the abdomen, retroperitoneum, and spine.
Aishwarya Holi, Karuna Rayamajhi, Satya Rijal, Niket Shah, Aaron Sousa, Gina Chacon Osorio   +5 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Short‐Term Outcomes of Advanced Pneumatic Compression Device Versus Usual Care Therapy for Head and Neck Cancer‐Related Lymphedema: A Multi‐Site Randomized Clinical Trial

Head &Neck, Volume 48, Issue 4, Page 1077-1087, April 2026.
ABSTRACT Background Two‐month outcomes of advanced pneumatic compression device (APCD) and usual care (UC) in Head and Neck Cancer survivors with previously untreated lymphedema were compared. Methods Participants in this multisite, randomized clinical trial were randomized to APCD or UC.
Barbara A. Murphy, Derek K. Smith, Cristina M. Kline‐Quiroz, Katrina M. Jensen, Ammar W. Sukari, Mihir K. Bhayani, Vikas Mehta, Harry Quon, Jennifer L. Shah, Christopher D. Willey, Neal E. Dunlap, Hoon K. Lee, Joseph M. Aulino, Sheila H. Ridner   +13 more
wiley   +1 more source

THYROIDITIS

Annals of Surgery, 1932
H M, Clute, F H, Lahey
openaire   +3 more sources

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source